NasserHHannaMD

Oncology • Indianapolis, IN

Associate Professor, Medicine, Indiana University School of Medicine

Join to view full profile

Dr. Hanna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hanna's full profile

Already have an account?

Office
535 Barnhill Dr
Rt 473
Indianapolis, IN 46202
Phone+1 317-278-0067
Is this information wrong?

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1998 - 2000
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1995 - 1998
University of Missouri-Columbia School of MedicineClass of 1995

Certifications & Licensure

IN State Medical License 1999 - 2025
IA State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Start of enrollment: 2006 Feb 23
Completed
Phase 2
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 3
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer Start of enrollment: 2005 May 01
Completed
Phase 1, Phase 2
Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer Start of enrollment: 2005 Jan 01
Terminated
Phase 2
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas Start of enrollment: 2006 Apr 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer Start of enrollment: 2006 Aug 01
Completed
Phase 2
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 1, Phase 2
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer Start of enrollment: 2007 Jun 01
Terminated
Phase 1, Phase 2
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Sutent + Taxol for Advanced Esophageal Cancer Start of enrollment: 2008 Aug 01
Completed
Phase 2
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers Start of enrollment: 2013 Mar 01
Completed
Not Applicable
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

EPR24-112: Lung Cancer in Never Smokers: The Role of Radon Exposure and Public Knowledge.
Marriam Ali, Ahmed Salih, Sasmith Menakuru, Vijaypal Dhillon, Nasser Hanna> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
Adenocarcinoma HarboringFusion Treated With Osimertinib: A Case Report.
Sunny Y Lai, Mya Tran, Noah H Richardson, Nasser H Hanna, Misty D Shields> ;JTO Clinical and Research Reports. 2024 Apr 1
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors.
Ryan Ashkar, Kenneth Kesler, Sandra K Althouse, Nasser H Hanna, Lawrence H Einhorn, Nabil Adra, King, J.> ;JAMA Oncology. 2024 Jan 1
1 citations
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski, Jyoti D Patel> ;The Oncologist. 2024 Jan 5
3 citations
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
Nasser Hanna, Frances A Shepherd, Frank V Fossella, Jose R Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thom...> ;Journal of Clinical Oncology. 2023 May 20
1 citations
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Ting Zhao, Sheng Liu, Nasser H Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
2 citations
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors.
Michael Cheng, Kenneth Kesler, Ryan Ashkar, Sandra K Althouse, Nasser H Hanna, Lawrence H Einhorn, Nabil Adra, King, J.> ;Journal of Clinical Oncology. 2023 Aug 10
4 citations
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?
Isamu Tachibana, Andre Alabd, Yan Tong, Alex Piroozi, Mohammad Mahmoud, Sean Q Kern, Timothy A Masterson, Nabil Adra, Richard S Foster, Nasser H Hanna, Lawrence H Einh...> ;Journal of Clinical Oncology. 2023 Aug 10
8 citations
Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).
Fadi Taza, Rafat Abonour, Mohammad Abu Zaid, Sandra K Althouse, Bilal Anouti, Reem Akel, Nasser H Hanna, Nabil Adra, Lawrence H Einhorn> ;Clinical Genitourinary Cancer. 2023 Apr 1
8 citations
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Canc...
Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Greg A Durm> ;Cancer. 2023 Jan 15
1 citations
Relations of perceived injustice to psycho-spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making.
Ekin Secinti, Wei Wu, Ellen F Krueger, Adam T Hirsh, Alexia M Torke, Nasser H Hanna, Nabil Adra, Gregory A Durm, Lawrence Einhorn, Roberto Pili, Shadia I Jalal, Cather...> ;Psycho-Oncology. 2022 Dec 1
8 citations
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.
Nabil Adra, David J Vaughn, Lawrence H Einhorn, Nasser H Hanna, Samuel A Funt, Matt Rosales, Ahsan Arozullah, Darren R Feldman> ;Investigational New Drugs. 2022 Oct 1
1 citations
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
Sandra Althouse, Clint Cary, Timothy Masterson, Richard S Foster, Ryan Ashkar, Nasser H Hanna, Lawrence H Einhorn, Nabil Adra, King, J.> ;The Journal of Urology. 2022 Sep 1
2 citations
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: ...
Fatemeh Ardeshir-Larijani, Sandra K Althouse, Ticiana Leal, Lawrence Eric Feldman, Taher Abu Hejleh, Malini Patel, Ryan D Gentzler, Adam Ryan Miller, Nasser H Hanna> ;Clinical Lung Cancer. 2022 Nov 1
4 citations
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B Garon, Giorgio V Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J M G...> ;European Journal of Cancer. 2022 May 1
100 citations
Advances in systemic therapy for non-small cell lung cancer
Meagan Elizabeth Miller, Nasser H. Hanna> ;BMJ. 2021 Nov 9
4 citations
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation.
Josiah An, Melissa Yan, Nanmeng Yu, Adithya Chennamadhavuni, Muhammad Furqan, Sarah L. Mott, Bradley T. Loeffler, Tim J. Kruser, Timothy L. Sita, Lawrence Eric Feldman...> ;Translational Lung Cancer Research. 2021 Aug 1
3 citations
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood ste...
Vaibhav Agrawal, Rafat Abonour, Mohammad Abu Zaid, Sandra Althouse, Ryan Ashkar, Costantine Albany, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra> ;Cancer. 2021 Oct 15
13 citations
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Nikhil Shukla, Nasser H. Hanna> ;Lung Cancer. 2021 Jun 28
6 citations
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
Ryan Ashkar, Darren R. Feldman, Nabil Adra, Mohammad Abu Zaid, Samuel Funt, Sandra K. Althouse, Susan M. Perkins, Christin I. Snow, Kayla Marie Lazzara, Lina M Sego, D...> ;Investigational New Drugs. 2021 May 24
5 citations
Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC.
Nikhil Shukla, Nasser H. Hanna, Greg Andrew Durm> ;JCO Oncology Practice. 2021 May 3
3 citations
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.
Ryan Nguyen, Laura B. Vater, Lava Timsina, Greg Andrew Durm, Katelin Rupp, Keylee Wright, Miranda H. Spitznagle, Brandy Paul, Shadia I. Jalal, Lisa Carter-Harris, Kare...> ;Plos One. 2021 Apr 16
1 citations
Measurement of patients’ acceptable symptom levels and priorities for symptom improvement in advanced lung cancer
Ellen Krueger, Ekin Secinti, Wei Wu, Nasser H. Hanna, G. Durm, Lawrence H. Einhorn, Shadia I. Jalal, Catherine E. Mosher> ;Supportive Care in Cancer. 2021 Mar 24
134 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker Jr, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain, Ishma...> ;Journal of Clinical Oncology. 2021 Mar 20
3 citations
Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Smal...
Nikhil Shukla, Sandra K. Althouse, Zachary S Meyer, Nasser H. Hanna, Greg Andrew Durm> ;Clinical Lung Cancer. 2021 Jan 23
Join now to see all

Other

Adjuvant systemic therapy in resectable non-small cell lung cancer
Hanna N
http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer
UpToDate, Wolters Kluwer Health - 2013-03-25

Press Mentions

Honoring a Father’s Life and LegacyNovember 17th, 2022
Cancer Physician-Scientist Offers Expertise on New Lung Cancer CT Screening RecommendationsMarch 12th, 2021
Practical Challenges in Patients with Stage III NSCLC Receiving Checkpoint Inhibitors After ChemoradiationFebruary 6th, 2020
Join now to see all